In recent weeks, providers and stakeholders across the health care system have raised concerns that the Part B Drug Payment Model proposed by the Centers for Medicare & Medicaid Services (CMS) lacks needed safeguards to protect patients from access barriers and reduced quality of care. A new issue brief released by Discern Health last week builds on these concerns, finding CMS has not yet presented a monitoring and evaluation plan for the Part B Drug Payment Model to mitigate the risk of harm to Medicare beneficiary access and quality of care.
CMS’ proposed Part B Drug Payment Model would be run by the Center for Medicare and Medicaid Innovation (CMMI). CMMI was set up to test new payment and delivery models and is required to evaluate each model to understand the impact on quality of care (including patient outcomes) and changes in program spending. This evaluation – and ongoing monitoring for unintended effects – is very important to ensure that Medicare patients are not harmed by any changes to the Medicare program.
Discern Health identified several gaps and risks in the Part B Drug Payment Model design, including:
- The mandatory participation requirement, which could disrupt care delivery that is already complex for many patients;
- A lack of necessary quality measures available to capture patient-reported quality outcomes;
- A failure to evaluate the impact on outcomes, such as survival and quality of life; and
- The broad scope of the model, which will necessitate immense resources for adequate monitoring and evaluation.